Promising NMOSD drug trial halted early – what happened?
NCT ID NCT03330418
First seen Apr 20, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tested an experimental drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that attacks the nerves. The goal was to see if RC18 could prevent relapses and slow disability. The trial was terminated early, so results are limited. Participants had to have had recent relapses and test positive for a specific antibody.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.